Welcome to our dedicated page for Centessa Pharmaceuticals plc American Depositary Shares news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals plc American Depositary Shares stock.
Centessa Pharmaceuticals plc (NASDAQ: CNTA) is a next-generation biopharmaceutical company based in Cambridge, Massachusetts, dedicated to transforming the traditional drug development model. By leveraging an asset-centric R&D approach at scale, Centessa is advancing a robust pipeline of highly validated programs led by industry-leading teams. Each program is managed by a Centessa subsidiary and supported by a centralized infrastructure and executive management team.
The company’s clinical-stage assets include:
- SerpinPC - A novel treatment for Hemophilia A and B, currently in Phase 2b trials. SerpinPC is a subcutaneously administered inhibitor of APC, aiming to provide effective treatment irrespective of severity or inhibitor status.
- LB101 - A cutting-edge PD-L1xCD47 LockBody, targeting solid tumors. LB101 is currently in a Phase 1/2a clinical trial, designed to selectively drive potent effector functions to the tumor micro-environment while minimizing systemic toxicity.
- ORX750 - An orally administered, highly selective orexin receptor 2 (OX2R) agonist for Narcolepsy Type 1 (NT1) and other sleep disorders, currently in its Phase 1 clinical study.
- MGX292 - Targeting Pulmonary Arterial Hypertension (PAH).
- Undisclosed programs targeting solid tumors.
Recent Achievements include:
- Phase 2b study PRESent-3 of SerpinPC showing promising preliminary results.
- FDA Fast Track designation for SerpinPC in treating Hemophilia B.
- Progress in LB101's Phase 1/2a clinical trial.
- Launch of the Phase 1 study for ORX750, with initial proof-of-concept data in sleep-deprived healthy volunteers expected later this year.
Centessa’s innovative approach and comprehensive pipeline aim to deliver transformational medicines to patients, setting a new standard of care. For more information, visit their official website at http://www.centessa.com/.
IMIDomics Inc. has established its Scientific and Business Advisory Boards to enhance its mission in developing precision medicines for immune-mediated inflammatory diseases (IMIDs) such as lupus and rheumatoid arthritis. The boards consist of leading experts including Dan Littman and Luisa Salter-Cid, aiding IMIDomics in leveraging its Precision Discovery Engine, which integrates extensive clinical data to innovate therapies for IMIDs. CEO Juan Harrison emphasizes the importance of advancing treatment options for these complex and often undertreated conditions.
Epizyme, Inc. has announced the appointment of two new members to its Board of Directors: Roy A. Beveridge, M.D., a clinical oncology executive, and Carol Stuckley, M.B.A., a seasoned pharmaceutical and financial leader. Beveridge brings over 30 years of experience in oncology and healthcare policy, while Stuckley offers 25 years of financial expertise from Pfizer. The company also announced the resignation of Andrew R. Allen, M.D., Ph.D., effective November 16, 2021. The leadership changes aim to enhance Epizyme's focus on epigenetic therapies and support its growth trajectory.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced promising topline results from a proof-of-concept study of SerpinPC in severe hemophilia A and B, showing an 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds. The company also provided proof-of-mechanism data for ZF874 in Alpha-1 Antitrypsin Deficiency. A $300 million financing facility was secured with Oberland Capital, strengthening the company's financial position. Centessa incurred a net loss of $40.2 million for Q3 2021, with cash and equivalents at $653.4 million, anticipated to fund operations until mid-2024.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will present at two upcoming investor conferences. The first is the Jefferies London Healthcare Conference on November 18, 2021, where the presentation will be available on-demand starting at 3:00 AM ET. The second is the Evercore ISI HealthCONx Conference on December 2, 2021, featuring a fireside chat at 4:20 PM ET. Access to live webcasts and archives will be available on the Centessa investor relations website.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced proof-of-mechanism data from its Phase 1 study of ZF874 for treating Alpha-1 Antitrypsin Deficiency (AATD). The study showed increases in functional Z-A1AT levels exceeding 11 micromolar in patients with the PiZZ genotype. One subject displayed reversible elevation in liver enzymes, prompting the company to expedite enrollment for upcoming studies. The expected Phase 2 study is set to refine dosing and is anticipated to start in 2Q 2022.
Centessa Pharmaceuticals (CNTA) and Schrödinger are collaborating to discover novel therapeutics targeting the orexin-2 receptor (OX2R), which plays a critical role in sleep disorders like narcolepsy. This partnership allows Orexia to utilize Schrödinger’s advanced computational platform, enhancing drug discovery capabilities. Orexia aims to leverage this collaboration for the development of orexin agonists addressing narcolepsy type 1 and other conditions characterized by excessive daytime sleepiness. The agreement includes milestone payments and royalties for Schrödinger.
Schrödinger (Nasdaq:SDGR) and Centessa Pharmaceuticals (Nasdaq:CNTA) announced an exclusive collaboration to discover novel therapeutics targeting the orexin-2 receptor (OX2R), relevant for sleep disorders like narcolepsy. This partnership marks the first large-scale application of Schrödinger's computational platform in orexin agonist development, leveraging Orexia’s structural biology capabilities. Orexia will manage preclinical research and commercialization, while Schrödinger will receive upfront payments and potential royalties on global sales. The collaboration aims to explore orexin agonists for various disorders characterized by excessive daytime sleepiness.
Centessa Pharmaceuticals (Nasdaq: CNTA) has appointed David Grainger, PhD, as its new Chief Innovation Officer, enhancing its executive leadership team. Dr. Grainger, a key advisor since the company's formation, will oversee scientific and research activities, shaping the development of therapeutic candidates. His appointment aligns with Centessa's goals for clinical and pre-clinical milestones. Previously, Dr. Grainger co-founded 28 biotech companies and has extensive experience in drug development.
Centessa Pharmaceuticals has announced a $300 million financing agreement with Oberland Capital, significantly boosting its available capital to over $900 million. This funding will support the advancement of its clinical and pre-clinical programs and enable strategic business development. The financing structure includes interest-only senior secured notes for six years. The initial $75 million was funded on October 4, 2021, with further options for funding available. This strategic move comes after a positive Phase 2 trial readout and sets the stage for potential registrational studies.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced positive topline results from the Phase 2a trial of SerpinPC, a treatment for severe hemophilia A and B. The study showed an 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% for spontaneous joint bleeds in the highest dose tested. The drug was found to be well-tolerated, with minimal adverse events reported. The company plans to initiate a global registrational program and will host a conference call to discuss findings.
FAQ
What is the current stock price of Centessa Pharmaceuticals plc American Depositary Shares (CNTA)?
What is the market cap of Centessa Pharmaceuticals plc American Depositary Shares (CNTA)?
What does Centessa Pharmaceuticals specialize in?
Where is Centessa Pharmaceuticals headquartered?
What is SerpinPC?
What stage is LB101 in?
What is the focus of ORX750?
Has SerpinPC received any special designations?
What kind of development model does Centessa Pharmaceuticals use?
What other programs are in Centessa's pipeline?
What recent achievements has Centessa Pharmaceuticals made?
How can I find more information about Centessa Pharmaceuticals?
